Undisclosed CDH17/GUCY2C BsADC / Hangzhou DAC Biotech - LARVOL DELTA

A novel 2+2 IgG-like bispecific antibody-drug conjugate with dual payloads for targeted therapy of heterogeneous gastrointestinal cancers (AACR 2026) - "This ADC agent also demonstrated potent cytotoxicity against both single and dual antigen-expressing tumor cells. The promising preclinical efficacy profile of this ADC support its potential as a targeted therapy for patients with advanced GI cancers, offering a new strategy to overcome treatment resistance and improve clinical outcomes."

ADC • Bispecific • Heterogeneity • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17 • GUCY2C

A novel 2+2 IgG-like bispecific antibody-drug conjugate targeting EBV GP220/350 and EGFR for selective treatment of nasopharyngeal carcinoma (AACR 2026) - "Epidermal growth factor receptor (EGFR) is also overexpressed in >80% of NPC cases and is a validated therapeutic target (e.g., cetuximab). Binding affinity, in vitro cytotoxicity and in vivo efficacy were assessed. DXA038-CPT113 showed superior activity both in vitro and in vivo compared to nimotuzumab-CPT113.This bispecific ADC represents a promising therapeutic strategy for EBV-positive NPC, addressing unmet needs in precision oncology."

ADC • Bispecific • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • EGFR